Studies from University of Pittsburgh in the Area of Cancer Vaccines Published.

"We have recently reported that chemotherapeutic agents in ultra low noncytotoxic concentrations may block the ability of tumor cells to suppress functional activation of dendritic cells (DCs). HCT-116 human colon cancer cells were treated with 0.5 nM paclitaxel (PAC) or 2 nM doxorubicin (DOX) with the aim of defining the immunogenic changes induced by ultra low noncytotoxic concentrations of antineoplastic chemotherapeutic agents," scientists in Pittsburgh, United States report (see also Cancer Vaccines).

"Genetic alterations were screened by DNA micro-array that revealed increased expression of genes involved in antigen processing and presentation, including the heat-shock …